Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-vaccine in Resected Prostate Cancer
NCT01197625Phase 2Unknown
- Sponsor
- Oslo University Hospital
- Start
- Sep 2010
- Primary completion
- Sep 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in prostate cancer (PCa), sponsored by Oslo University Hospital. Status: unknown.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01197625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01197625.